At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 245 enrolled
Drug / intervention
LY2127399 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
In Brief
A Phase 2 clinical trial evaluating LY2127399 and Placebo for Relapsing-Remitting Multiple Sclerosis. Completed, enrolled 245 participants across 63 sites in 13 countries.
Detailed Summary
To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing-Remitting Multiple Sclerosis
CountriesBulgaria, Czechia, France, Germany, Hungary, Israel, Poland, Romania, Russia, Serbia, Slovakia, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedApr 2009
Primary CompletionFeb 2011
Study CompletionJun 2012
TodayJul 2026
First PostedApr 17, 2009
Enrollment StartApr 1, 2009
Primary CompletionFeb 1, 2011
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.2 years ago
Interventions
LY2127399drug
Administered via Injection
Placebodrug
Administered via Injection